Pharvaris (PHVS) Income towards Parent Company (2020 - 2026)
Pharvaris (PHVS) reported Income towards Parent Company of -$45.8 million for Q1 2026, up 6.35% on a YoY basis from -$43.0 million in Q1 2025, and up 77.36% quarter-over-quarter from -$202.2 million in Q4 2025.
Pharvaris (PHVS) Income towards Parent Company (2020 - 2026) Analysis & Trends
Pharvaris has reported Income towards Parent Company for 7 years, with the latest figure at -$45.8 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 6.35% year-over-year to -$45.8 million; the trailing twelve-month figure through Mar 2026 stood at -$239.6 million (down 142.97% YoY), and the FY2025 full-year result was -$198.5 million, down 36.64% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$45.8 million, up from -$202.2 million in the prior quarter.
- The five-year high for Income towards Parent Company was $51.8 million in Q2 2025, with the low at -$202.2 million in Q4 2025.
- Historically, Income towards Parent Company has averaged -$28.3 million across 5 years, with a median of -$30.4 million in 2024.
- Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 75.8% — and 2025, when it plunged 464.49%.
- Pharvaris' Income towards Parent Company stood at -$39.7 million in 2022, then advanced by 13.23% to -$34.4 million in 2023, then fell by 4.04% to -$35.8 million in 2024, then sank by 464.49% to -$202.2 million in 2025, then jumped by 77.36% to -$45.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$45.8 million (Q1 2026), -$202.2 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Pharvaris | 28.66 Bn | 28.37 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.78 Mn |
| Dec 31, 2025 | -202.21 Mn |
| Sep 30, 2025 | -43.43 Mn |
| Jun 30, 2025 | 51.78 Mn |
| Mar 31, 2025 | -48.88 Mn |
| Dec 31, 2024 | -35.82 Mn |
| Sep 30, 2024 | -45.92 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | -30.40 Mn |
| Dec 31, 2023 | -34.43 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | 23.84 Mn |
| Mar 31, 2023 | -24.32 Mn |
| Dec 31, 2022 | -39.68 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | -17.98 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -10.78 Mn |
| Jun 30, 2021 | 18.31 Mn |